A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|82|2|75-82

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.2, 2012-02, pp. : 75-82

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 356-360

Karger

Access to resources Recommend Favorite

Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 333-337

Karger

Access to resources Recommend Favorite

Phase I study of gemcitabine, cisplatin, and S‐1 combination therapy for patients with untreated advanced biliary tract cancer

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 9, 2015-09 ,pp. : 669-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1671-1675

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two Consecutive Phase II Studies of 5-Fluorouracil/Leucovorin/Mitomycin C and of Gemcitabine in Patients with Advanced Biliary Cancer

By  

Oncology, Vol. 56, Iss. 3, 1999-04 ,pp. : 177-180

Karger

Access to resources Recommend Favorite